Hot Topic in tema di neoplasie del Colon: Durata ottimale della chemioterapia adiuvante nei tumori del Colon
|
|
- Sherilyn Doyle
- 5 years ago
- Views:
Transcription
1 Convegno Nazionale AIOM Giovani 2018 News in Oncology Hot Topic in tema di neoplasie del Colon: Durata ottimale della chemioterapia adiuvante nei tumori del Colon Daniele Rossini U.O. di Oncologia Medica Universitaria Azienda Ospedaliero-Universitaria Pisana Istituto Toscano Tumori
2 Adjuvant Therapy for Colon Cancer STAGE II III Low risk Follow up Or consider Fluoropyrimidine in MSS High risk Fluoropyrimidine (not in MSI-H) Or consider FOLFOX or XELOX FOLFOX or XELOX Or consider Fluoropyrimidine AIOM Guidelines 2017
3 Adjuvant Therapy for Colon Cancer Stage III 50% cured by surgery alone Adjuvant chemo (fp+oxa) 25% cured by surgery and chemo Stage III CRC pts fit for fluropyrimidine+oxaliplatin 25% relapsed despite surgery and chemo Courtesy of C. Antoniotti Adapted from Meyerhardt et al, ASCO Ann Meet 2017
4 Neurotox in MOSAIC: How much? Grade 3 peripheral sensory neuropathy during treatment was 12.5% (0.2% of the patients in the LV5FU2 group) 18 months: 24.1% had symptoms of any grade 0.7% reporting grade 3 symptoms. At 48 months: 15,4 % had symptoms of any grade 0.7% reporting grade 3 symptoms Andrè et al, JCO 2009
5 Chapter One: We Have an IDEA
6 Less is
7 IDEA Collaboration What is the IDEA Collaboration? Prospective Pooled Analysis 6 Phase III Trials For Patients with Stage III Colon Cancer
8 Study Design 3 months Stage III Prior surgey R 1:1 6 months Investigator s choice FOLFOX or CAPOX
9 IDEA: Who? Trials (Group) N Patients (N=12834) Stage TOSCA 2402 III II High-Risk SCOT 3983 III II High-Risk Tumor Location Colon Colon Rectum Treatments FOLFOX4 CAPOX mfolfox6 CAPOX IDEA France 2010 III Colon mfolfox6 CAPOX Additional trial-specific comparison FOLFOX4+Be v vs FOLFOX alone 62 None 37 None 51 C III Colon mfolfox6 3 y of celecoxib vs placebo HORG 708 III II High-Risk Total N Pts (Stage III): Colon FOLFOX4 CAPOX ACHIEVE 1291 III Colon mfolfox6 CAPOX 35 None 48 None 37 Median follow-up time, m
10 Rationale for Non-inferiority Margin IDEA Consensus (Oncology and Patient Advocates) 12% relative risk increase (upper 95% CI) Non-Inferiority Margin: DFS HR=1.12 Piaggio, et al, Jama 2012
11 Statistical Design Primary Endpoint: disease-free survival (DFS) Time from date of randomization (enrollment) to the earliest date of relapse, secondary colorectal primary tumor, or death due to all causes Primary Analysis Population: Modified Intent-to-treat: randomized and received any dose of treatment Pre-planned Subgroup Analyses: Regimen T/N Stage
12 Results: Adverse Events But also: Neutropenia, Febrile Neutropenia, Thrombocytopenia, Nausea, Mucositis, Fatigue and Hand-foot syndrome Grothey et al., NEJM 2018
13 Results DFS Qian Shi, et al, ASCO 2017
14 Results DFS 3 years DFS 74.6% vs 75.5% HR: % CI ( ) P for not inferiority=0.11 Grothey et al, NEJM 2018
15 Chapter Two: Dissecting an IDEA
16 Preplanned Analysis Two preplanned analysis: Regimen T/N
17 Results Preplanned Analyses: T/N Favors 3m Favors 6m Grothey et al, NEJM 2018
18 Preplanned Analysis - Regimen Qian Shi, et al, ASCO 2017
19 FOLFOX vs CAPOX Patients are not stratified for regimen Grothey et al, NEJM 2018
20 Results Preplanned Analyses: T/N Favors 3m Favors 6m Grothey et al, NEJM 2018
21 Results Recap The DFS non-inferiority of 3m oxaliplatin-based adjuvant treatment was not established in overall stage III colon cancer DFS comparison by T/N showed no differences DFS comparison by regimen showed that CAPOX is not FOLFOX HR < 1.12
22 Chapter Three: Finding an IDEA
23 Results Subgroup Analyses: Risk Groups
24 Stratification: high vs low risk Are high and low risk pts are balanced between the two treatment arms? SCOT trial TOSCA trial IDEA France
25 What is IDEA message?
26 IDEA recommendations Grothey et al, NEJM 2018
27 IDEA recommendations Grothey et al, NEJM 2018
28 NCCN Guidelines NCCN Guidelines v2.2018
29 My clinical practice in stage III Choose CAPOX T4 or N2: 6 months T3N1: 1) Plan 6 months 2) At least 3 months of CAPOX or FOLFOX If Neurotox G2-3 develops, then hold oxaliplatin.
30 Chapter Four: A new IDEA
31 Gao et al. BMC 2018 Turner et al. J Am Co Sur 2018 Role of Time Stage III N=18491 Stage III N=72057
32 Role of MMR Status, Histology and BRAF Status Zaanan et al. Jama Oncol 2018; Soliman et al. Dis Colon Rectum 2018; Andrè JCO 2015
33 Liquid biopsy in Stage III Stage III Tie et al, ASCO 2018
34 DYNAMIC-III trial Primary endpoint: To demonstrate that a chemotherapy decision based on the presence or absence of circulating tumour DNA after surgery, will be more effective than standard of care treatment.
35 Take home message - In stage III, 3 months of oxaliplatin based therapy is not inferior than 6 months. - In low risk of stage III, the oncologists can discuss potential trade-offs between side effects and efficacy of adjuvant therapy. - cfdna could be useful in the future to guide the adjuvant decision.
Adjuvant/neoadjuvant systemic treatment of colorectal cancer
5th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology Belgrade, June 19 th 2018 Adjuvant/neoadjuvant systemic treatment of colorectal cancer Carlotta Antoniotti Polo Oncologico
More informationOptimal adjuvant therapy for colon cancer is FOLFOX for 6 cycles YES
Optimal adjuvant therapy for colon cancer is FOLFOX for 6 cycles YES Bassel F. El-Rayes 1 Background Standard of care for resected stage III colon cancer is six months of adjuvant oxaliplatin-based therapy
More informationS u p p o r t e d b y a n i n d e p e n d e n t E d u c a t i o n a l G r a n t f r o m B a y e r
EXPERTS KNOWLEDGE SHARE with Prof. Köhne, Dr. Modest and Dr. Vecchione Madrid (Spain) Sunday September 10 th 2017 S u p p o r t e d b y a n i n d e p e n d e n t E d u c a t i o n a l G r a n t f r o m
More informationIs There a New Standard of Care for Adjuvant Therapy in Colon Cancer? When is 3 Months Enough?
Is There a New Standard of Care for Adjuvant Therapy in Colon Cancer? When is 3 Months Enough? Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA 1 Disclosure Ad Board: Genentech Honorarium:
More informationAdjuvant treatment Colon Cancer
ESMO Preceptorship Colorectal Cancer, October 2016 Singapore Adjuvant treatment Colon Cancer Claus-Henning Köhne University Clinic for Onkology und Haematology Oldenburg, Germany Aim of the lecture Adjuvant
More informationThe International Duration Evaluation of Adjuvant Chemotherapy study: implications for clinical practice
Editorial The International Duration Evaluation of Adjuvant Chemotherapy study: implications for clinical practice Marwan Fakih Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive
More informationIl paziente anziano con malattia oncologica avanzata: il tumore del colon-retto
Milano 05.10.2018 Il paziente anziano con malattia oncologica avanzata: il tumore del colon-retto Salvatore Corallo U.O.C. Oncologia Medica IRCCS Istituto Nazionale dei Tumori Milano CRC in elderly patients
More informationASCO 2017 updates in Colorectal and Gastric Cancers. May Cho, M.D.
ASCO 2017 updates in Colorectal and Gastric Cancers May Cho, M.D. Relevant financial relationships in the past twelve months by presenter or spouse/partner: None The speaker will directly disclosure the
More informationNOVITA IN TEMA DI TERAPIA DEL CARCINOMA DEL COLON-RETTO
Congresso AIOM Giovani Perugia, 9 luglio 2016 NOVITA IN TEMA DI TERAPIA DEL CARCINOMA DEL COLON-RETTO Carlotta Antoniotti Polo Oncologico Azienda Ospedaliero-Universitaria Pisana Università di Pisa What
More informationAIOM GIOVANI Perugia, Luglio 2017
AIOM GIOVANI 2017 Perugia, 07-08 Luglio 2017 Scelta delle linee successive nel paziente RAS e BRAF wild-type con particolare accento su nuovi bersagli terapeutici Francesca Battaglin U.O.C. Oncologia Medica
More informationAdjuvant therapy in older adults: controversies and challenges - Colorectal cancer -
International Society of Geriatric Oncology Lisbon October 23 rd 25t h 2014 Adjuvant therapy in older adults: controversies and challenges - Colorectal cancer - Claus-Henning Köhne Klinik für Onkologie
More informationDisclosures. Clinical and molecular features to guide adjuvant therapy. Personalized Medicine - Decision Tools -
Disclosures Clinical and molecular features to guide adjuvant therapy Daniel Sargent Professor of Biostatistics & Oncology Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis
More informationDALLA CAPECITABINA AL TAS 102
DALLA CAPECITABINA AL TAS 102 Milano 29 settembre 2016 LE PROSPETTIVE NELLA RICERCA Armando Santoro Humanitas Cancer Center THE 1,2.AND 3 LINE CHEMOTHERAPY IN CRC M BEVACIZUMAB AFLIBERCET RAS wt RAS mu
More informationThird Line and Beyond: Management of Refractory Colorectal Cancer
Third Line and Beyond: Management of Refractory Colorectal Cancer George A. Fisher MD PhD Stanford University 1 Overview Defining the chemo refractory and intolerant Agents approved in 3 rd line setting
More informationCetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer
Cetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer Cetuximab with Chemotherapy (CT) as First-Line Treatment for Metastatic Colorectal Cancer (mcrc): Analysis of
More informationRetrospective analysis of the effect of CAPOX and mfolfox6 dose intensity on survival in colorectal patients in the adjuvant setting
ORIGINAL ARTICLE CAPOX AND mfolfox6 DOSE INTENSITY AND CLINICAL OUTCOMES IN STAGE III CRC, Mamo et al. Retrospective analysis of the effect of CAPOX and mfolfox6 dose intensity on survival in colorectal
More informationChemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA
Chemotherapy for resectable liver mets: Options and Issues Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy regimens in 1 st line mcrc Standard FOLFOX-Bev FOLFIRI-Bev
More informationPrognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Bruno Vincenzi Università Campus Bio-Medico di Roma
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients Bruno Vincenzi Università Campus Bio-Medico di Roma Colorectal cancer 3 rd most common cancer worldwide Approximately
More informationProgress and Challenges in the Adjuvant Treatment of Stage II & III Colon Cancer
Progress and Challenges in the Adjuvant Treatment of Stage II & III Colon Cancer Professor Eva Segelov Monash Health and Monash University (with thanks to A/P Jeremy Shapiro) Melbourne, Australia Apr 2017
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationAdjuvant chemotherapy for high-risk stage II and stage III colon cancer: timing of initiation and optimal duration
JBUON 2018; 23(3): 568-573 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com REVIEW ARTICLE Adjuvant chemotherapy for high-risk stage II and stage III colon cancer:
More informationClinical interpretation and validity of trials: when do they become practice changing
Clinical interpretation and validity of trials: when do they become practice changing Alberto Sobrero Oncologia Medica 1 Ospedale Policlinico San Martino Genova Italy Clinical trials: the 5 phases and
More informationThe role of Maintenance treatment Appropriate endpoints according to ESMO consensus
ESMO Preceptorship Programme Colorectal Cancer Singapore-October 20-22 2016 JY Douillard, MD, PhD, CMO ESMO The role of Maintenance treatment Appropriate endpoints according to ESMO consensus MAINTENANCE
More informationAdjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
More informationBRAF Testing In The Elderly: Same As in Younger Patients?
EGFR, K-RAS, K BRAF Testing In The Elderly: Same As in Younger Patients? Nadine Jackson McCleary MD MPH Gastrointestinal Oncology Dana-Farber/Harvard Cancer Care Boston, MA, USA Outline Colorectal cancer
More informationToxicity by Age Group. Old Factor 1: Age. Disclosures. Predicting survival in metastatic colorectal cancer. Personalized Medicine - Decision Tools -
Disclosures Predicting survival in metastatic colorectal cancer Daniel Sargent, PhD Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis Genomic Health Personalized Medicine -
More informationColon cancer: Highlights. Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano
Colon cancer: Highlights Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano Agenda 1) Metastatic colorectal cancer First-line treatment molecularly unselected: FOLFOXIRI-bev (CHARTA trial) Later-line
More informationCetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS)
Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS) C Bokemeyer, E Staroslawska, A Makhson, I Bondarenko, JT Hartmann,
More informationAdvances in Chemotherapy of Colorectal Cancer
Advances in Chemotherapy of Colorectal Cancer Richard M. Goldberg Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Disease Settings Adjuvant Therapy MOSAIC, FOLFOX Andre
More informationAdjuvant therapies for large bowel cancer Wasantha Rathnayake, MD
LEADING ARTICLE Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD Consultant Clinical Oncologist, National Cancer Institute, Maharagama, Sri Lanka. Key words: Large bowel; Cancer; Adjuvant
More informationAdjuvant treatment for stage III colon cancer
ESMO Preceptorship Programme Rectal cancer Singapur November 2017 Adjuvant treatment for stage III colon cancer Andrés Cervantes Disclosures Consulting and advisory services, speaking or writing engagements,
More informationAdjuvant treatment for stage II and III Colon Cancer. Ramon Salazar Catalan Institute of Oncology
Adjuvant treatment for stage II and III Colon Cancer Ramon Salazar Catalan Institute of Oncology Disclosures R. Salazar has served in a consultant or advisory role for Amgen, Merck Serono, Taihoo, MSD,
More informationPET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationDoes it matter which chemotherapy regimen you partner with the biologic agents?
Does it matter which chemotherapy regimen you partner with the biologic agents? Yes, it does matter! Axel Grothey Disclosures Research Funding to MAYO Clinic Genentech Bayer Eisai Pfizer Imclone Potential
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationColorectal Cancer: Critical review
AIOM POST-ASCO 2018 Updates and Review from Chicago Milano, June 15-16, 2018 Colorectal Cancer: Critical review Alfredo Falcone, MD Department of Oncology and Translational Medicine University of Pisa
More informationMOSAIC study: Actualization of Overall Survival (OS) with 10 years follow up and evaluation of BRAF by GERCOR and MOSAIC investigators
MOSAIC study: Actualization of Overall Survival (OS) with 10 years follow up and evaluation of BRAF by GERCOR and MOSAIC investigators Thierry André, Armand de Gramont, Benoist Chibaudel, Annemilaï Raballand,
More informationADJUVANT CHEMOTHERAPY FOR RECTAL CANCER
ESMO Preceptorship Programme Colorectal Cancer Barcelona November, 25-26, 2016 ADJUVANT CHEMOTHERAPY FOR RECTAL CANCER Andrés Cervantes Professor of Medicine OLD APPROACH TO RECTAL CANCER Surgical resection
More informationConvegno Nazionale AIOM Giovani 2016: News in Oncology. Daniele Alesini. Istituto Nazionale dei Tumori Regina Elena
Convegno Nazionale AIOM Giovani 2016: News in Oncology Daniele Alesini Istituto Nazionale dei Tumori Regina Elena Something Old Something New Something Borrowed Something Blue DOCETAXEL: BACK AND FORTH
More informationMEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER
MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationXXV Corso Nazionale TSLB: evoluzione o ri(e)voluzione?
XXV Corso Nazionale TSLB: evoluzione o ri(e)voluzione? Marcatori predittivi di efficacia nel carcinoma del colon: DESTRO verso SINISTRO conta? Dott. Matteo Clavarezza S.C. Oncologia Medica RAS metastatic
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationGI Tumor Board 3/8/2018. Case #1 IDEA. Case #1 Question #1 What is the next step in management?
GI Tumor Board Edward Kim George Poultsides Naseem Esteghamat Kenzo Hirose May Cho Alan Venook Arta Monjazeb Margaret Tempero George Fisher Andrew Ko Daniel Chang Thomas Semrad Sisi Haraldsdottir Case
More informationSergio Bracarda MD, Head, Department of Oncology Azienda USL Toscana Sud-Est Istituto Toscano Tumori (ITT) Ospedale San Donato Arezzo, Italy
Sergio Bracarda MD, Head, Department of Oncology Azienda USL Toscana Sud-Est Istituto Toscano Tumori (ITT) Ospedale San Donato Arezzo, Italy Milano, 3 marzo 2017 Prostata: Castration resistant HIGHLIGHTS
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationReview of the ESMO consensus conference on metastatic colorectal cancer Basic strategies and groups. Chemotherapy and targeted agents in 1st line
ESMO Preceptorship Programme Colorectal Cancer Valencia, 18th May 2018 Review of the ESMO consensus conference on metastatic colorectal cancer Basic strategies and groups Chemotherapy and targeted agents
More informationAdjuvant therapy in pancreatic cancer Monotherapy for whom? JL VAN LAETHEM, MD,PhD
Adjuvant therapy in pancreatic cancer Monotherapy for whom? JL VAN LAETHEM, MD,PhD Efficacy Parameters in adjuvant monochemotherapy Randomized studies in resectable PDAC Regimen DFS HR (p) OS HR (p) 5-yr-OS
More informationmcrpc 2014 TRA EVOLUZIONE E RIVOLUZIONE: COME ORIENTARSI NEL LABIRINTO DELLE TERAPIE
mcrpc 2014 TRA EVOLUZIONE E RIVOLUZIONE: COME ORIENTARSI NEL LABIRINTO DELLE TERAPIE IL CARCINOMA PROSTATICO, UNA MALATTIA ETEROGENEA? RAZIONALE E RISULTATI DEL TRATTAMENTO CHEMIOTERAPICO ASSOCIATO ALL
More informationUse of Taxanes in Older Breast Cancer Patients
SIOG Guidelines Update 2014: Use of Taxanes in Older Breast Cancer Patients Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Fundamental steps Task Force (TF) on
More informationImmunotherapy for dmmr metastatic colorectal cancer. Prof.dr. Kees Punt Dept. Medical Oncology AUMC
Immunotherapy for dmmr metastatic colorectal cancer Prof.dr. Kees Punt Dept. Medical Oncology AUMC Active specific immunotherapy (ASI) in stage II-III colon cancer Vaccination with autologous tumor + BCG
More informationTherapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer
Therapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer Axel Grothey, M.D., Professor of Oncology, Clinical and Translational Science Division of Medical Oncology Mayo Clinic, Rochester,
More informationManaging mcrc Across Disease Continuum: Front-Line Therapy and Treatment Beyond Progression
Managing mcrc Across Disease Continuum: Front-Line Therapy and Treatment Beyond Progression Guillermo Méndez, MD Sección Oncología Hospital de Gastroenterología Bonorino Udaondo Carlos B. Udaondo y Fundación
More informationRationale for VEGFR-targeted Therapy in RCC
Rationale for VEGFR-targeted Therapy in RCC EIKCS, Budapest, May 2013 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial Management Group Honoraria Astra Zeneca + + + Astellas
More informationProgress towards an individualized approach to therapy: colorectal cancer
Progress towards an individualized approach to therapy: colorectal cancer Alan P. Venook, M.D. University of California, SF GIST: PET change after 4 weeks imatinib Multiple liver and upper abdominal 18
More informationINMUNOTERAPIA EN CANCER COLORRECTAL METASTASICO. CCRm MSI-H NUEVO ESTANDAR EN PRIMERA LINEA Y/O PRETRATADOS?
INMUNOTERAPIA EN CANCER COLORRECTAL METASTASICO CCRm MSI-H NUEVO ESTANDAR EN PRIMERA LINEA Y/O PRETRATADOS? V. Alonso Servicio de Oncologia Medica H. U. Miguel Servet Zaragoza MSI-H mcrc Clinical and Pathological
More informationLa strategia terapeutica del carcinoma del colon metastatico
Dalla Capecitabina al TAS-102 Milano, 29 settembre 2016 La strategia terapeutica del carcinoma del colon metastatico Gianluca Masi U.O. di Oncologia Medica Universitaria Azienda Ospedaliero-Universitaria
More informationWill All Adjuvant Therapy Trials Be Negative in RCC?
Will All Adjuvant Therapy Trials Be Negative in RCC? Tim Eisen Eleventh European International Kidney Cancer Symposium 29-30 April 2016 Crowne Plaza Barcelona Fira Center, Barcelona, Spain Tim Eisen -
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationMEETING SUMMARY ASCO GI, SATURDAY JANUARY 17 TH 2015
Supported by an Independent Educa1onal Grant from MEETING SUMMARY ASCO GI, SATURDAY JANUARY 17 TH 2015 BY DR. GUILLEM ARGILES, BARCELONA, SPAIN Cancers of the Lower GI Tract RAISE: A RANDOMIZED, DOUBLE-BLIND,
More informationOverview. What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013
What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013 Overview Staging and Workup Resectable Disease Surgery Adjuvant therapy Locally
More informationPerioperative chemotherapy for colorectal cancer livermetastases: what is the optimal strategy?
Perioperative chemotherapy for colorectal cancer livermetastases: what is the optimal strategy? Prof Eric Van Cutsem, MD, PhD Digestive Oncology Leuven, Belgium Eric.VanCutsem@uzleuven.be A classical case
More informationUpdate on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
More informationCOMETS: COlorectal MEtastatic Two Sequences
COMETS: COlorectal MEtastatic Two Sequences A Phase III Multicenter Trial Comparing Two Different Sequences of Second/Third Line Therapy (Irinotecan/Cetuximab Followed By FOLFOX-4 vs. FOLFOX-4 Followed
More informationNovel Chemotherapy Agents for Metastatic Breast Cancer. Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX
Novel Chemotherapy Agents for Metastatic Breast Cancer Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX New Chemotherapy Agents in Breast Cancer New classes of drugs Epothilones Halichondrin
More informationCarcinoma del retto: Highlights
Carcinoma del retto: Highlights Stefano Cordio Struttura Complessa di Oncologia Medica ARNAS Garibaldi Catania Roma 17 Febbraio 2018 Disclosures Advisory Committee, research funding and speakers bureau
More informationADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS. Andrés Cervantes. Professor of Medicine
ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS Andrés Cervantes Professor of Medicine 1995 One option Advances in the treatment of mcrc 2000
More informationCANCER METRONOMIC THERAPY GASTROINTESTINAL CANCERS
AIOM Meeting Milan, 26 February 2016 CANCER METRONOMIC THERAPY GASTROINTESTINAL CANCERS Lisa Salvatore Polo Oncologico Azienda Ospedaliero-Universitaria Pisana Università di Pisa My Agenda The metronomic
More informationForum of Clinical Oncology
HeSMO 5(2) 2014 1 7 DOI: 10.2478/fco-2014-0006 Forum of Clinical Oncology Projecting Event-Based Analysis Dates in Clinical Trials: An Illustration Based on the International Duration Evaluation of Adjuvant
More informationTerapia neoadyuvante en cáncer de recto Estado del arte Mauricio Lema Medina MD Clínica de Oncología Astorga / Clínica SOMA - Medellín, Colombia
Terapia neoadyuvante en cáncer de recto Estado del arte Mauricio Lema Medina MD Clínica de Oncología Astorga / Clínica SOMA - Medellín, Colombia Temario Generalidades Adyuvancia en colon y recto FU / Capecitabina
More informationCARCINOMA DEL COLON-RETTO: COSA DICONO LE LINEE GUIDA. Dr.ssa Foltran Luisa Oncologia medica Pordenone
CARCINOMA DEL COLON-RETTO: COSA DICONO LE LINEE GUIDA Dr.ssa Foltran Luisa Oncologia medica Pordenone Convegno Regionale AIOM FVG, Palmanova, 14 Maggio 2016 COLORECTAL CANCER FOLLOW-UP Objectives Intensive
More informationPhysical activity, Obesity, Diet and Colorectal Cancer Prognosis. Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA
Physical activity, Obesity, Diet and Colorectal Cancer Prognosis Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA Colorectal Cancer Incidence ~148,000 cases in US annually and ~50,000
More informationFabienne Warmerdam Zuyderland
GE Fabienne Warmerdam Zuyderland Disclosure ASCO 2017 travelgrant Pfizer CRC ADJUVANT Less is more? More is More! 1 Less is more? Perspectief INT-0035 stadium III (niets vs 5-FU) 6.5-jaars OS 46% vs. 60%
More informationLa strategia terapeutica per il trattamento del carcinoma del colon-retto metastatico
VI Corso Nazionale Eventi Formativi AIOM-SIAPEC Roma,15 Giugno 2016 La strategia terapeutica per il trattamento del carcinoma del colon-retto metastatico Francesco Di Costanzo Direttore SC Oncologia Medica
More informationjournal of medicine The new england Duration of Adjuvant Chemotherapy for Stage III Colon Cancer abstract
The new england journal of medicine established in 1812 March 29, 2018 vol. 378 no. 13 Duration of Adjuvant Chemotherapy for Stage III Colon Cancer A. Grothey, A.F. Sobrero, A.F. Shields, T. Yoshino, J.
More informationΚίκα Πλοιαρχοπούλου. Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών
Κίκα Πλοιαρχοπούλου Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών Time (months) Survival outcomes in mcrc have progressively improved over the past two decades Treatment options for many patients Multidisciplinary
More informationOPTIMISING OUTCOMES FOR PATIENTS WITH ADVANCED COLORECTAL CANCER
OPTIMISING OUTCOMES FOR PATIENTS WITH ADVANCED COLORECTAL CANCER E-Learning Module Stavros Gkolfinopoulos 1, Demetris Papamichael 1, George Pentheroudakis 2 1. Cyprus Oncology Centre, Nicosia, Cyprus 2.
More informationThe TAILORx Trial: A review of the data and implications for practice
The TAILORx Trial: A review of the data and implications for practice Angela DeMichele, MD, MSCE Jill & Alan Miller Endowed Chair in Breast Cancer Excellence Professor of Medicine and Epidemiology University
More informationHigh risk stage II colon cancer
High risk stage II colon cancer Joel Gingerich, MD, FRCPC Assistant Professor Medical Oncologist University of Manitoba CancerCare Manitoba Disclaimer No conflict of interests 16 October 2010 Overview
More informationPROSTATA MULTIDISCIPLINARITA IN URO-ONCOLOGIA INTEGRAZIONE TERAPIA SISTEMICA-TRATTAMENTO LOCALE. Dr.ssa Ori Ishiwa Dr Sergio Bracarda
15 anno di fondazione del GUONE MULTIDISCIPLINARITA IN URO-ONCOLOGIA Aviano, 10 settembre 2010 INTEGRAZIONE TERAPIA SISTEMICA-TRATTAMENTO LOCALE PROSTATA Dr.ssa Ori Ishiwa Dr Sergio Bracarda UOC Oncologia
More informationManagement of Advanced Colorectal Cancer in Older Patients
Review Article [1] April 15, 2005 By Stuart M. Lichtman, MD, FACP [2] Many elderly individuals have substantial life expectancy, even in the setting of significant illness. There is evidence to indicate
More informationChemotherapy options and outcomes in older adult patients with colorectal cancer
Critical Reviews in Oncology/Hematology 72 (2009) 155 169 Chemotherapy options and outcomes in older adult patients with colorectal cancer Muhammad W. Saif a,, Stuart M. Lichtman b a Yale University School
More informationTarge:ng HER2 in Metasta:c Breast Cancer in 2014
Targe:ng HER2 in Metasta:c Breast Cancer in 2014 Kimberly L. Blackwell MD Professor Department of Medicine and Radia:on Oncology Duke University Medical Center Director, Breast Cancer Program Duke Cancer
More informationTrial record 1 of 1 for: GO28341 Previous Study Return to List Next Study
1 von 5 11.12.2013 09:04 A service of the U.S. National Institutes of Health Trial record 1 of 1 for: GO28341 Previous Study Return to List Next Study A Study of GDC-0068 in Combination With Fluoropyrimidine
More informationConflicts of Interest GI Malignancies: An Update on Current Treatment Options
Conflicts of Interest GI Malignancies: An Update on Current Treatment Options Nothing to disclose Trevor McKibbin, PharmD, MS, BCOP Clinical Specialist, Hematology/Oncology Winship Cancer Institute of
More informationMSI and other molecular markers: how useful are they? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany
MSI and other molecular markers: how useful are they? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Disclosure slide I Member of advisory boards for AMGEN, ROCHE I Speaker
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationAdjuvant Chemotherapy for Elderly Women with Breast Cancer: Matti S. Aapro, M.D. IMO Clinique de Genolier Switzerland
SIOG Berlin October 2009 Adjuvant Chemotherapy for Elderly Women with Breast Cancer: Immediate Benefit and Long-Term Risk Matti S. Aapro, M.D. IMO Clinique de Genolier Switzerland 1 2 BACKGROUND MESSAGE
More informationAntiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab
Micro-ambiente tumorale. Antiangiogenici e immunoterapia: miti e realtà Milano, 11 Ottobre 2016 Antiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab Francesco Grossi U.O.S. Tumori
More informationTobias Engel Ayer Botrel 1,2*, Luciana Gontijo de Oliveira Clark 1, Luciano Paladini 1 and Otávio Augusto C. Clark 1
Botrel et al. BMC Cancer (2016) 16:677 DOI 10.1186/s12885-016-2734-y RESEARCH ARTICLE Open Access Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated
More informationManagement of Patients with Colorectal Cancer
Management of Patients with Colorectal Cancer Elsevier Office of Continuing Medical Education Independent Conference Highlights of the ASCO-GI 2018 Symposium Disclaimer The views expressed in the following
More informationDevelopment of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical modulation, Oral fluoropyrimidines, Developmentof combination chemotherapy
ESMO Preceptorship Colorectal Cancer Colorectal ESMO Cancer Preceptorship Valencia May Program 20-21st 2016 Prague May 22-23rd 2014 Development of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical
More informationWhat s New in Colon Cancer? Therapy over the last decade
What s New in Colon Cancer? 9/19/2014 Michael McNamara, MD Therapy over the last decade Cytotoxic chemotherapy - 5FU ( Mayo, Roswell, Infusional) - Xeloda (01 ) - Oxaliplatin (02 ) - Irinotecan (96 ) Anti-
More informationtrial update clinical
clinical trial update by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UMPC Cancer Centers In order to provide the most up-to-date and efficacious care to their patients, oncologists must
More informationJonathan Dickinson, LCL Xeloda
Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy
More informationFirst line treatment in metastatic colorectal cancer
First line treatment in metastatic colorectal cancer Claus-Henning Köhne University Clinic Onkology and Haematology North West German Cancer Center (NWTZ) A non authorised version of ESMO guidelines was
More informationPanel Two: Evidence for Use of Maintenance Therapy
Panel Two: Evidence for Use of Maintenance Therapy Evidence for Use of Maintenance Therapy Richard L. Schilsky University of Chicago Comprehensive Cancer Center What is maintenance therapy? The continued
More informationUpper Gastrointestinal Cancers in the Elderly. Choo Su Pin Senior Consultant Medical Oncology National Cancer Centre Singapore
Upper Gastrointestinal Cancers in the Elderly Choo Su Pin Senior Consultant Medical Oncology National Cancer Centre Singapore Gastric Cancer --High Global Burden Global Cancer Deaths % of all cancer (2008)
More informationColorectal Cancer Update Dr. Barb Melosky
Colorectal Cancer Update 2017 Dr. Barb Melosky bmelosky@bccancer.bc.ca Disclosure Research Support/P.I. Honoraria/Advisory Board Bayer Roche, Amgen, Bayer, Lilly Objectives 1) Demonstrate knowledge of
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More information